

Brian Robert Keegan M.D., Ph.D.

59 One Mile Road Ext., Suite G
East Windsor NJ 08520
609.443.4500 (Office)
609.426.0530 (Fax)

Practice

7/2010-Present Partner - **Windsor Dermatology**
Co-Research Director - **Psoriasis Treatment Center of Central New Jersey**

Academic Teaching Faculty

7/2010-Present University Medical Center at Princeton – Department of Medicine, Dermatology Div.

Board Certification

2010-Present Dermatology and Cutaneous Surgery

AAD Committees

2014-Present American Academy of Dermatology Enduring Materials Committee – Advisory Board
2013-2014 DermClips

Editorial Advisory Board

2015-Present Journal of Clinical and Aesthetic Dermatology
2013-2014 DermClips

Professional Societies

2010-Present National Psoriasis Foundation
2010-Present New Jersey Dermatology Society – Central Chapter
2007-Present American Academy of Dermatology
1998-Present American Medical Association

Advisory/Speaker Board

2017-Present Pfizer
2017-Present Lilly
2016-Present Novartis
2016-Present Actelion
2014-2015 Purecap Pharmaceuticals
2014-2015 Taro Pharmaceuticals
2013-2014 University of Colorado Dermatology and Infectious Disease
2013-Present Janssen Pharmaceuticals
2013-2015 Aqua Pharmaceuticals
2012-Present Valeant/Medicis/Onset Pharmaceuticals
2012-Present Warner Chilcott/Activis/Allergan Pharmaceuticals
2012-Present Promius Pharmaceuticals
2012-2015 Galderma Franchise
2012-2014 Neostrata
2010-Present Abbott/Abbvie Pharmaceuticals
2010-2015 Tranzderm Solutions

Education

7/2007-6/2010 Dermatology Residency,
University of Miami Miller School of Medicine, Miami, Florida

7/2006-6/2007 Transitional Medicine Internship,
St. Vincent's Catholic Medical Center, New York City, New York

8/1998-5/2006 **New York University**, New York City, New York
 Degrees: M.S., 9/2002
 Ph.D., 1/2004
 M.D., 5/2006
 Thesis: Genetic Regulation of Cardiac Specification in Zebrafish

9/1992-6/1996 **University of Utah**, Salt Lake City, Utah
 Degree: B.S., 6/1996 Major: Biology

Leadership/Volunteer Positions

2016-Present Co-Research Director - **Psoriasis Treatment Center of Central New Jersey**
 2015-Present Editorial Advisory Board - Journal of Clinical and Aesthetic Dermatology
 2014-Present American Academy of Dermatology Enduring Materials Committee – Advisory Board
 2013-Present Medical Advisory Board for Princeton Hospital and Wellness Center
 2013 Volunteer Dermatology Care – Africa
 2010-Present Princeton Area Free Cancer Screening
 2013-2014 DermClips Editorial Committee
 2008-2010 Camillus House indigent clinics
 2008-2010 Florida Keys Heath fair
 2008-2010 CIR Liaison
 2002-2005 Fundraiser, New York City Marathon & Charitable Organizations
 2000-2003 Student Representative, Committee on Student Life
 2000-2003 Student Chair, Committee on Residential Environment
 2000-2002 Chief Advisor, NYU Student Council
 1999-2000 Student Representative, Liaison Committee on Medical Education
 1999-2000 President, NYU Student Council
 1999-2000 Student Treasurer, American Medical Association
 1999 Co-Organizer, Class of 2003 Medical Student Orientation
 1998-1999 Class Vice-President, NYU Student Council
 1992-1996 Captain/Student-Athlete, University of Utah Men’s Swimming Team

Honors, Awards & Grants

2015-2016 New Jersey Top Docs
 2013-2015 Smartest Dermatologist Award
 2010 Sorrel Resnik Research Award
 2010 George Ioannides Resident Teaching Award
 2008 Miami Dermatology Society George Elgart Award
 2008-2010 Tumor Necrosis Factor Alpha and Recalcitrant Venous Leg Ulcers: A Pilot Study to Determine the Effect of Adalimumab Therapy IRB-20080048-01
 2007 Outstanding Intern Achievement
 2006 Alpha Omega Alpha Membership
 2005 Hearst Scholar for Excellence in Research
 2005 Department of Dermatology – Introduction to Terminology Teaching Tool
 2004 Department of Medicine – Clinical/Pathological Conference Presentation Award
 2002-2004 NIH Developmental Genetics Pre-Doctoral Training Grant
 2000 AMA Leadership Training Award
 1998-2006 NIH MSTP M.D./Ph.D. Training Fellowship
 1996 Michael D. Wallace Award for Leadership
 1996 University of Utah Undergraduate Research Award
 1996 Biology Undergraduate Research Fellowship
 1995 Howard Hughes Undergraduate Research Fellowship
 1993-1996 USA Olympic Development Team
 1993 USA Swimming under-18 National Champion
 1992-1996 NCAA Student/Athlete Swimming Scholarship
 1992-1996 Dean’s List

Selected Oral Presentations

- 2017 Current treatments in Psoriasis - NPF
- 2016 Advancements in Psoriasis Care – NJ Derm Society
- 2016 Lifestyle and Psoriasis - NPF
- 2015 Dr. Reddy Pharmaceuticals – Skin care safety
- 2014 Princeton Hospital – Skin care and YOU
- 2012 Fitness and Wellness U-steam
- 2013 CentraState Hospital - Healthy skin in 2013
- 2012 Princeton Wellness Center – Skin care, fact or fiction
- 2012 CentraState Hospital - Skin Cancer awareness: Recognition, Treatment and Prevention
- 2012 Princeton Wellness Center - Summer Skin Care to reduce Skin Cancer
- 2011 Princeton Wellness Center - Skin Cancer awareness: Recognition, Treatment and Prevention
- 2010 Miami Dermatology Society - Tumor Necrosis Factor Alpha and Recalcitrant Venous Leg Ulcers: A Pilot Study to Determine the Effect of Adalimumab
- 2009 Florida Dermatology Society – Adalimumab for Recalcitrant Venous Leg Ulcers, Early Experience
- 2004 Thesis Defense - Genetic Regulation of Cardiac Specification in Zebrafish
- 2003 Skirball Developmental Genetics Symposium - Retinoic acid signaling and its role in patterning cardiac progenitors
- 2003 3rd European Conference on Zebrafish and Medaka Genetics and Development - Retinoic acid signaling patterns anterior lateral plate mesoderm
- 2003 3rd Biannual New York University M.D./Ph.D. Conference - Early roles for retinoic acid signaling in zebrafish embryos February

Research Studies

- 2017 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis. Sponsored by Leo Pharma A/S.
- 2017 A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis of the Scalp. Sponsored by Celgene Corporation.
- 2017 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Comparative Efficacy of CNTO1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen.
- 2017 An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals.
- 2017 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Explore changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment with Secukinumab, Compared to Placebo, and Up to 52 Weeks of Treatment with Secukinumab in Adult Patients with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.
- 2017 An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis. Sponsored by Regeneron
- 2017 An Open-Label, Observational Study Evaluating Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel.
- 2017 A Phase 2A Randomized Double Blind Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Pfizer.
- 2017 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly
- 2017 A Phase 3 Trial Comparing the Efficacy and Safety of LEO 90100 Aerosol Foam with the Aerosol Foam Vehicle Used Twice Weekly as Long-Term Maintenance Therapy in Subjects with Psoriasis Vulgaris. Sponsored by Leo Pharma A/S.
- 2017 A Randomized, Double-blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults with Mild to Moderate Atopic Dermatitis. Sponsored by DS Biopharma.
- 2016 A Randomized, Placebo Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects with Moderate Chronic Plaque Type Psoriasis. Sponsored by Lycera Corp.
- 2016 Protocol I6T-MC-AMAF A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate-to-Severe Plaque Psoriasis Sponsored by Eli Lilly

2016 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD). Sponsored by Glenmark Pharmaceuticals Ltd.

2016 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of KD-025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. Sponsored by Kadmon.

2016 A 52-Week, Multi-Center, Randomized, Double-Blind, Study of Secukinumab (300mg) to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index and Investigators Global Assessment After 12 Weeks of Treatment, Compared to Ustekinumab, and to Assess Long-Term Safety, Tolerability, and Efficacy in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.

2016 An Open-Label, Observational Study Evaluating Topicort Topical Spray 0.25% (desoximetasone) in Patients with Scalp Psoriasis. Sponsored by Jerry Bagel.

2016 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed Therapy with Apremilast. Sponsored by Amgen

2016 An Open-Label, Observational Study Evaluating Topicort Topical Spray 0.25% (desoximetasone) BID in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel.

2016 A Phase IIB, Randomized, Double-Blind, Randomized, Placebo Controlled, Parallel, Multicenter, Dose Ranging, Study To Evaluate the Efficacy and Safety Profile of PF-04965842 in Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Pfizer.

2015 A Multi-Center, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly and Company.

2015 An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

2015 A Propective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor. Sponsored by Actelion Pharmaceuticals US, Inc.

2015 A Phase IV, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis. Sponsored by Celgene Corporation.

2015 An Open-Label Study of Dupilimab in Patients with Atopic Dermatitis who Participated in Previous Dupilimab Clinical Trials. Sponsored by Regeneron Pharmaceuticals, Inc.

2015 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilimab Dose Regimens Administered as Monotherapy For Maintaining Treatment Response in Patients with Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.

2015 Single-Center, Two Phase, Pilot Study to Evaluate the Efficacy and Safety of Combining Otezla® (apremilast) 30mg BID in Combination with Narrowband UVB (nUVB) Phototherapy, to Determine Effectiveness of Otezla® in Promoting Maintenance of Response in the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Jerry Bagel, MD

2015 Randomized, Phase 2, Double-Blind, Vehicle-Controlled Trial Evaluate the Safety and Efficacy of Q301 Cream in Patients with Moderate to Severe Atopic Dermatitis. Sponsored by Quriert Therapeutics.

2014 A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilimab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.

2014 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pego in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UBC Biopharma, SPRLing the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen Research & Development, LLC

2014 A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilimab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.

2014 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pego in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UCB Biopharma, SPRL

2014 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen Research & Development, LLC

2014 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and Assess Safety and Tolerability Up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis. Sponsored by Novartis Pharmaceuticals Corporation

2014 Characterization of Chronic Inflammatory Skin Disease. Sponsored by TRBIO

2014 A Small Methods Study Involving Electronic Data Collection in Normal Care Settings with Adult Psoriasis Patients Who Have A High Level of Clearance (As Determined by sPGA of 0 or 1) And Are Currently Being Treated With A Biologic. Sponsored by HRA

2014 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects with Psoriasis Vulgaris. Sponsored by Leo Pharma

2014 A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Valeant

2014 A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis. Sponsored by AbbVie

2014 A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis. Sponsored by Novartis

2013 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene® (augmented betamethasone dipropionate) Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis. Sponsored by Promius

2013-2014 A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator controlled (ustekinumab), double-blind within dose groups of BI 655066). Sponsored by Boehringer

2013 – 2014 A Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of the Investigational Drug in Plaque Psoriasis Patients. Sponsored by Maruho

2013 – 2014 A randomized, double-blind, vehicle-controlled, multicenter, parallel-group clinical trial to assess the safety and efficacy of Azelaic Acid Foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea. Sponsored by Bayer

2013 A 12 Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsored by Eli Lilly

2013 Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients with Moderate to Severe Plaque Psoriasis. Sponsored by Eli Lilly

2013 – 2014 A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Lotion 0.05% versus Vehicle Lotion in Subjects with Plaque Psoriasis. Sponsored by Therapeutics Inc.

2013 – 2014 An Observational Study to Assess Patient Satisfaction and Control of Psoriasis with Taclonex Topical Suspension and Effect on Quality of Life. Sponsored by LEO Pharma

2013 Evaluation of HylatopicPlus Foam, HylatopicPlus Cream, and Aquaphor in Mild to Moderate Atopic Dermatitis Subjects to Assess Subject Experience Product Characteristics. Sponsored by Onset Dermatologics

2013 A Phase 3 Trial Comparing Once Daily Treatment with LEO 90100 Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) with Vehicle in Subjects with Psoriasis Vulgaris. Sponsored by LEO Pharma

2013 Clinical Trial To Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults Sponsored by Anterios

2012 A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. Sponsored by Amgen

2012 A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a “Subject-tailored” Maintenance Dosing Approach of Ustekinumab in Subjects with Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen

2012-2013 A Phase 3 Randomized, Double-Blind, 12-week Vehicle-Controlled, Parallel-Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects with Papulopustular Rosacea, Followed by a 40-Week Investigator-Blinded Extension Comparing the Long-Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Sponsored by Galderma

2012-2013 Phase II Randomized Double Blinded Placebo Controlled, Multiple-Dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways As Well As on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-Type Psoriasis. Sponsored by Novartis

2012-2013 A Phase 2 Study Comparing Treatment With LEO 90100 with Betamethasone Dipropionate in LEO 90100 Vehicle and Calcipotriol in LEO 90100 Vehicle in Subjects with Psoriasis Vulgaris. Sponsored by LEO Pharma

2012-2013 A Phase 2 A Phase 2 Study Comparing Treatment with LEO 90100 with Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects with Psoriasis Vulgaris. Sponsored by LEO Pharma

2012-2013 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly

2012-2013 A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Assess the Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily in Subjects with Moderate to Severe Facial Erythema Associated with Rosacea. Sponsored by Galderma

2012-2013 Clinical Trial to Evaluate Sweat Production in Subjects with Primary Axillary Hyperhidrosis in Adults. Sponsored by Anterios, Inc.

2011-2012 A Multicenter, Observational, Non-interventional, Narrative Study to Evaluate Patient-Reported Experiences of Living with Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen

2011-2012 Collection of Blood Samples for Developing Assays to Measure Drug Levels and Anti-Drug Antibody Levels in Subjects Treated With Humira® (adalimumab) or Cimzia® (certoluzimab pegol.) Sponsored by Prometheus

2011-2013 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis who have Lost a Satisfactory Response to Adalimumab

2011- 2014 A Phase 3, multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis. Sponsored by Celgene

2011 Calcipotriol Plus Betamethasone Dipropionate Topical Suspension Compared to Betamethasone Dipropionate in the Topical Suspension Vehicle, Calcipotriol in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Psoriasis Vulgaris. Sponsored by Leo

2010 A Single Center, Single-Arm, Open Label, Pilot Trial to Evaluate the Safety, Effectiveness, and Impact on Quality of Life of Adalimumab (Humira®) Treatment in patients with Vitiligo. Investigator sponsored

2010 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis. Sponsored by Amgen

2010 A Phase 2 Study, Evaluating the Safety and Efficacy of Calcipotriol 25 mcg/g + Hydrocortisone 10 mg/g Ointment Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on Intertriginous Areas. Sponsored by Leo

2010 A Single Center, Open-label, Pilot Trial to Evaluate the Effectiveness and Safety of HUMIRA in Combination with Narrowband UVB (NB-UVB) Phototherapy for the Treatment of Psoriasis. Investigator sponsored

2010 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Amgen

2010-Present Observational Post-Marketing Safety Surveillance Registry of Enbrel (etanercept) for the Treatment of Psoriasis. Sponsored by Amgen

2010- Present A 10-Year , Post-Marketing, Observational, Registry to Assess Long Term Safety of Humira in Adult Patients with Chronic Plaque Psoriasis. Sponsored by Amgen/Abbvie

2010- Present A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic therapy Including Biologics. Sponsored by Janssen

2010- 2012 Phase II Randomized double blinded placebo controlled, multiple-dose regimen study to assess the rate of histological clearance and effect on molecular pathways as well as on biomarkers of 12 months secukinumab 300mg s.c treated patients with chronic plaque type psoriasis. Sponsored by Novartis

2010- Present Tranzderm Solutions: Advanced solutions to transdermal drug delivery. South Dakota State University

2008-2010 Tumor Necrosis Factor Alpha and Recalcitrant Venous Leg Ulcers: A Pilot Study to Determine the Effect of Adalimumab Therapy IRB-20080048-01 Robert Kirsner M.D. Ph.D. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine

2005-2007 Clinical description and genetic analysis in pediatric dermatology. Topics include: corticosteroid use in children under two, Blaschkitis, Blau syndrome and progeroid Ehlers-Danlos syndrome. Seth Orlow M.D. Ph.D. Department of Dermatology, NYU School of Medicine Julie Schaffer M.D. Department of Dermatology, NYU School of Medicine

2005-2007 Clinical description of a patient with a nasal cutaneous T-cell lymphoma who had an excellent response to treatment. Jo-Ann Latkowski M.D. Department of Dermatology, NYU School of Medicine

2005-2007 A retrospective analysis of the role of sperm morphology in *in-vitro* fertilization. Jamie Grifo M.D. Ph.D. Department of Obstetrics and Gynecology, NYU School of Medicine

2000-2004 Genetic regulation of heart formation. Including embryonic origin and patterning of cardiac precursors. Deborah Yelon Ph.D. Developmental Genetics Department, NYU School of Medicine

1996-1998 Genetic regulation of mitochondrial morphology. Focusing on the role of a high molecular weight GTPase, DNMI, in maintenance of organelle morphology. Janet Shaw Ph.D. Department of Biology, University of Utah
1994-1996 Spatial segregation of molecular messages. Including development of new molecular techniques for expression analysis. Darryl Kropf Ph.D. Department of Biology, University of Utah

Publications

- Retreatment With Brodalumab Results in High Response Rates in Patients With Psoriasis After Treatment Interruption
Armstrong A, Blauvelt A, Wu JJ, **Keegan BR**, Rastogi S, Pillai R, Israel RJ – In review
- Efficacy of Brodalumab in Ustekinumab-Naive and -Experienced Patients With Moderate-to-Severe Plaque Psoriasis
Hsu S, Green L, **Keegan BR**, Kircik L, Rastogi S, Pillai R, Israel RJ – In review
- Bagel J, Nelson E. **Keegan BR** Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis – In press
- Fox JD, Baquerizo-Nole KL, **Keegan BR**, Macquhae F, Escandon J, Espinosa A, Perez C, Romanelli P, Kirsner RS
Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study. *Int Wound J*. 2016 Oct;13(5):963-6.
- Keegan BR** Desoximetasone 0.25% Spray for the Relief of Scaling in Adults With Plaque Psoriasis. *Journal of Drugs and Dermatology* 2015 Aug
- Keegan BR**, Bagel J. Plaque psoriasis management: a 2013 update. *Expert Reviews in Dermatology* 2013 Aug(8).
- Keegan BR**, Schlam E. Step-by-Step Evaluation of Cutaneous Small Vessel Vasculitis. *Practical Dermatology* 2008 Dec;5(12):46-9.
- Waxman JS, **Keegan BR**, Roberts RW, Poss KD, Yelon D. Hoxb5b acts downstream of retinoic acid signaling in the forelimb field to restrict heart field potential in zebrafish. *Developmental Cell*. 2008 Dec;15(6):923-34.
- Keegan BR**, Romagosa Y, Kirser RS. MRSA in Dermatology. *Journal of Investigative Dermatology* 2008 Nov;128(11):2566.
- Lanuti EL, **Keegan BR**, Wolf IW, Romanelli M, Ruiz P, Romanelli P. Dermatological Complications in Transplant Patients and Composite Tissue Allotransplant Pathology. *Transplant Pathology*. 2008 Dec.
- Keegan BR**, Kamino H, Fangman W, Shin HT, Orlow SJ, Schaffer JV. "Pediatric blaschkitis": expanding the spectrum of childhood acquired Blaschko-linear dermatoses. *Pediatric Dermatology*. 2007 Nov-Dec;24(6):621-7.
- Keegan BR**, Barton S, Sanchez X, Berkeley AS, Krey LC, Grifo J. Isolated teratozoospermia does not affect in vitro fertilization outcome and is not an indication for intracytoplasmic sperm injection. *Fertility & Sterility*. 2007 Dec;88(6):1583-8.
- Schoenebeck JJ, **Keegan BR**, Yelon D. Vessel and blood specification override cardiac potential in anterior mesoderm. *Developmental Cell*. 2007 Aug;13(2):254-67.
- Schaffer JV, Chandra P, **Keegan BR**, Heller P, Shin HT, Widespread granulomatous dermatitis of infancy: an early sign of Blau syndrome. *Archives of Dermatology*. 2007 Mar;143(3):386-91.
- Keegan BR**, Feldman JL, Begemann G, Ingham PW, Yelon D. Retinoic acid signaling restricts the cardiac progenitor pool. *Science*. 2005 Jan 14;307(5707):247-249.
- Keegan BR**, Meyer D, Yelon D. Organization of cardiac chamber progenitors in the zebrafish blastula. *Development*. 2004 Jul;131(13):3081-91.
- Yelon D, Feldman JL, **Keegan BR**. Genetic regulation of cardiac patterning in zebrafish. *Cold Spring Harbor Symposium in Quantitative Biology*. 2002;67:19-25.

Keegan BR, Feldman JL, Lee DH, Koos DS, Ho RK, Stainier DY, Yelon D. The elongation factors Pandora/Spt6 and Foggy/Spt5 promote transcription in the zebrafish embryo. *Development*. 2002 Apr;129(7):1623-32.

Fukushima NH, Brisch E, **Keegan BR**, Bleazard W, Shaw JM. The GTPase effector domain sequence of the Dnm1p GTPase regulates self-assembly and controls a rate-limiting step in mitochondrial fission. *Molecular Biology of the Cell*. 2001 Sep;12(9):2756-66.

Otsuga D, **Keegan BR**, Brisch E, Thatcher JW, Hermann GJ, Bleazard W, Shaw JM. The dynamin-related GTPase, Dnm1p, controls mitochondrial morphology in yeast. *Journal of Cell Biology*. 1998 Oct 19;143(2):333-49.

Roeder AD, Hermann GJ, **Keegan BR**, Thatcher SA, Shaw JM. Mitochondrial inheritance is delayed in *Saccharomyces cerevisiae* cells lacking the serine/threonine phosphatase PTC1. *Molecular Biology of the Cell*. 1998 Apr;9(4):917-30.

Interests

Include: volunteerism, travel, cooking and time with my family.